AACHEN, Germany–(BUSINESS WIRE)–Hemovent
GmbH announced today that it has closed on $5.2 million in a Series B
financing round, with the expectation of a regulatory approval of its
MOBYBOX™ ECMO / ECLS system this year.
The MOBYBOX™ System is a self-contained and fully integrated
ExtraCorporeal Membrane Oxygenation (ECMO) / ExtraCorporeal Life Support
(ECLS) system designed with an ultimate focus on safety, ease of use,
mobility, and performance in order to support or replace heart and lung
function in the event of cardiac and/or respiratory failure.
“There was significant interest from a variety of institutional and
strategic investors in this round,” said Christof Lenz, a
co-founder and CEO of Hemovent. “We now have sufficient financial
resources with which to commence roll-out of our initial product
MOBYBOX™ as soon as we receive EU regulatory approval. This Series B
cash infusion also gives us the means to seek FDA clearance in due
Earlier this year, Hemovent announced that it has been certified under
the ISO 13485:2016 quality management system (QMS) international
standard, which management believes is the next-to-last step in the CE
marking process for its MOBYBOX™ System.
Hemovent also previously announced it had successfully completed a GLP
standardized in vivo study for long-term (7 days) use of its MOBYBOX™
System, designed for a wide range of indications: from ExtraCorporeal
Life Support (ECLS) to ExtraCorporeal CO2 Removal
Hemovent is an emerging medical device company with a proprietary
platform technology for heart and lung support.
CAUTION: The Hemovent ECMO/ ECLS System is not approved for human use
APR, Ronald Trahan Associates